["{\n\"step_by_step_thinking\": \"The question describes an experimental new drug that increases incretin levels by preventing degradation at the endothelium. This leads to increased glucose-dependent insulin production. Incretins are hormones like glucagon-like peptide-1 (GLP-1) that stimulate insulin secretion. Sitagliptin is a dipeptidyl peptidase-4 inhibitor that prevents the degradation of incretins, allowing them to increase insulin production. Glimepiride and pioglitazone are sulfonylureas and thiazolidinediones respectively, which directly stimulate insulin release or sensitize tissues to insulin. Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that increases glucose excretion, thereby reducing hyperglycemia. Considering the mechanisms of action described in the question and the provided documents, sitagliptin has a mechanism most similar to this new experimental drug.\",\n\"answer_choice\": A"]